1. Home
  2. Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss

Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss

Author/s: 
Mohit Sodhi, Ramin Rezaeianzadeh, Abbas Kezouh, Mahyar Etminan
Date Added: 
February 12, 2024
Journal/Publication: 
JAMA
Publisher: 
American Medical Association
Publication Date: 
October 5, 2023
Issue: 
18
Volume: 
330
Pages: 
1795-1797
URL: 
Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss
Type: 
Clinical Research Results
Format: 
Article
DOI (1): 
10.1001/jama.2023.19574
PMID (1): 
37796527
Keywords 
weight loss
body weight
obesity
diabetes
Gastroenterology
MeSH 
glucagon-like peptide 1
Off-Label Use
Pancreatitis
weight loss
Bupropion
naltrexone
Gastroparesis

RPR Commentary

Estimated rates of various adverse GI events in patients taking GLP1 receptor agonists. James W. Mold, MD, MPH

Abstract

This database study examines the association between glucagon-like peptide 1 agonists (eg, semaglutide, liraglutide) used for weight loss and reports of gastrointestinal adverse events.

Text Availability

Free full text